INTRODUCTION
The most commonly prescribed triple therapy, consisting of use of a proton pump inhibitor with clarithromycin and amoxicillin, remains the recommended first-choice treatment for Helicobacter pylori infection. 1 2 3 One major problem with this therapy, as well as with other H pylori eradication regimens, is unsatisfactory eradication rates largely due to the increased resistance to antibiotics, primarily to clarithromycin. 4 5 6 In addition, adverse effects are experienced by about 5% to 30% of patients receiving H pylori eradication therapy and further contribute to treatment failure. 7 Measures to overcome these problems include the use of probiotics, which are live microbial food ingredients that are beneficial to health. 8 The rationale for the use of probiotics as adjunctive treatment for H pylori infection is based on the results of studies that have
shown that various lactobacilli (eg, Lactobacillus johnsonii La1, L acidophilus CRL 639, L casei), or their metabolic products, can inhibit or kill H pylori in vitro. 9 10 A recent systematic review 7 evaluated the effects of supplementation with probiotics on H pylori eradication rates and side effects of anti-H pylori treatment. Fourteen randomised controlled trials (RCTs) of varying methodological quality involving 1671 patients were identified. In patients with H pylori infection, probiotic supplementation improved eradication rates. In two RCTs that evaluated patients with eradication failure, probiotic supplementation also improved eradication rates.
Probiotics reduced therapy-related side effects overall and individual symptoms of diarrhoea, epigastric pain, nausea, and taste disturbance.
Opponents of using a meta-analytical approach to assess the efficacy of probiotics argue that the beneficial effects of probiotics seem to be strain specific, thus, pooling data on different strains may result in misleading conclusions. A more favourable approach is to perform a meta-analysis that evaluates the effect of administering a clearly defined probiotic preparation (single or in combination). Given these considerations, the aim of the current review was to update and synthesise the available clinical trial evidence of the likely effects of S boulardii given in addition to standard eradication therapy on major clinical outcomes related to H pylori eradication. The choice of the probiotic S boulardii was determined by the fact that it is widely available and commonly used in many countries.
METHODS
The guidelines from the Cochrane Collaboration for undertaking and reporting the results of a systematic review and meta-analysis 11 and the PRISMA statement 12 were followed for this systematic review and meta-analysis.
Criteria for considering studies for this review
All relevant RCTs that compared use of S boulardii alone or during H pylori eradication therapy with use of placebo or no treatment were eligible for inclusion.
Participants of any age had to be H pylori-infected subjects, as assessed by generally accepted methods (ie, the 13 C-urea breath test [UBT] , histopathology, or the rapid urease test). The primary outcome measure was the rate of H pylori eradication, which had to be confirmed by a negative 13 C-UBT or other generally accepted method at least 4 weeks after treatment. The secondary outcome measures were the frequencies of adverse effects (overall and specific). The adverse effects of interest were any common gastrointestinal adverse effects that occurred during anti-H pylori therapy, including diarrhoea, taste disturbance, nausea, vomiting, bloating, loss of appetite, abdominal pain, constipation, and the need for discontinuation of the H pylori therapy.
Search methods for identification of studies
The Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library), MEDLINE, and EMBASE databases were searched for relevant studies in 
Data collection and analysis
Three reviewers using a standardised approach independently undertook the literature search, data extraction, and quality assessment. The data sought included baseline characteristics of the patients, details of the H pylori eradication therapy, and details related to the use of experimental and control interventions (including dose and duration), type of outcome measure (primary vs secondary), methods of checking H pylori status, and/or assessment of side effects. Minor disagreements were resolved by discussion.
Assessment of risk of bias in included studies
The reviewers independently, but without being blinded to the authors or journal, assessed the risk of bias in the studies that met the inclusion criteria. The Cochrane Collaboration's tool for assessing risk of bias was used, which includes the following criteria: adequacy of sequence generation, allocation concealment, and blinding of participants, personnel and outcome assessors; and extent of loss to follow-up, ie, the proportion of patients in whom the investigators were not able to determine outcomes (incomplete outcome data). In all cases, an answer of 'yes' indicates a low risk of bias, and an answer of 'no' indicates a high risk of bias. 13 
Measures of treatment effect
The dichotomous outcomes, the results for individual studies, and pooled statistics are reported as the risk ratio (RR) between the experimental and control groups with 95% confidence intervals (95% CI). The weighted mean difference (WMD) between the treatment and control groups was selected to represent the difference in continuous outcomes (with 95% CI). analyses were based on the random effects model if it was still considered appropriate to pool the data.
Assessment of reporting biases
To test for publication bias, we planned to use a test for asymmetry of the funnel plot proposed by Egger et al. 15 This test detects funnel plot asymmetry by determining whether the intercept deviates significantly from zero in a regression of the normalized effect estimate (estimate divided by its standard error) against precision (reciprocal of the standard error of the estimate) weighted by the reciprocal of the variance of the estimate (on StatsDirect, version 2.3.8). However, the publication bias was not formally assessed using a funnel plot due to the small number of studies (<10) included in the analyses of the primary and secondary outcome measures.
Data synthesis (Statistical methods)
The data were analysed using Review Manager (RevMan) [Computer program. 
Subgroup analysis and sensitivity analyses
For the primary outcome, pre-planned subgroup analysis based on age (adults vs children) was performed. Additionally, when there was statistically significant heterogeneity in the primary outcome across studies, sensitivity analyses were planned to determine the impacts of allocation concealment (adequate versus inadequate and/or unclear) and attrition (<20% versus ≥20%). The latter were not performed, as there was no heterogeneity in the primary outcome.
RESULTS
The literature search yielded 894 articles, of which six were reviewed in full text (figure 1). 16 17 18 19 20 21 Of these studies, five RCTs 17 18 19 20 21 met the inclusion criteria.
All were published in English. These trials randomised a total of 1307 patients, of which 1227 were followed up. Table 1 summarises the characteristics of the included studies. The characteristics of the excluded trials, with reasons for exclusion, are available upon request. Four studies enrolled only adults, 17 18 19 21 and one RCT 20 (n=90) was undertaken exclusively in children (age range: 3 to 18 years). The sample size ranged from 43 to 661 participants. In all studies, S boulardii was used in addition to standard triple therapy consisting of a proton pump inhibitor and two antibiotics.
In all included trials, clarithromycin was one of the antibiotics used. The daily dose of S boulardii ranged from 500 mg 18 20 to 750 mg 21 to 1000 mg. 17 19 Two RCTs 17 18 were placebo controlled; in the remaining three trials, 19 20 21 there was no additional intervention in the control group. Except for one multi-centre trial, 19 the included studies were single-centre trials. The studies were undertaken in countries such as Italy (one RCT 18 ), Korea (one RCT 21 ), Romania (one RCT 20 ) , and Turkey (two RCTs 17 19 ).
Risk of bias in included studies
With the exception of one RCT by Cremonini et al., 18 all included trials had a number of methodological limitations (see table 2 ).
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Effects of interventions Primary outcome: H pylori eradication rates
Data regarding the effects of S boulardii supplementation on H pylori eradication rates were available from four trials, 17 18 20 21 which reported data from 915 participants (825 adults and 90 children) (figure 2). In two RCTs, the eradication rate was a primary outcome; 20 21 in the remaining two RCTs, 17 18 it was a secondary outcome.
We found a significant difference between the S boulardii-supplemented group and the control group with respect to H pylori eradication rates (four RCTs, n=915, RR 1.13, 95% CI 1.05 to 1.21). Of the 460 patients in the S boulardii group, 370 (80%, 95% CI 77% to 84%) experienced eradication compared with 324 of the 455 patients (71%, 95% CI 67% to 75%) in the control group. Thus, the administration of S boulardii along with the standard therapy resulted in a 9% higher absolute eradication rate (ARR 9%, 95% CI 3.6% to 14%). The number needed to treat (NNT) was 11 (95% CI 7 to 28). The pooled results of the three RCTs conducted in adults 17 18 21 showed a statistically significant increase in the eradication rate in favour of S boulardii compared with placebo or no treatment (3 RCTs, n=825, RR 1.12, 95% CI 1.04 to 1.22).
Secondary end points: adverse effects and compliance
Data regarding therapy-related adverse effects were available from all five of the included trials (figure 3). We found a significant difference between the S boulardiisupplemented group and the control group with respect to the risk of overall adverse effects (five RCTs, n=1305, RR 0.46, 95% CI 0.3 to 0.7). Of the 665 patients in the S 27 .8%) in the control group. Thus, the coadministration of S boulardii with the standard eradication therapy resulted in an 11.4% lower absolute adverse effects rate (ARR 11.4%, 95% CI 7.3% to 15.6%). The number needed to treat was 9 (95% CI 7 to 14).
In regard to specific adverse effects, the risk of therapy-related diarrhoea was statistically lower in the S boulardii group compared with the control group (four RCTs, n=1215, 5.6% vs 12.2%, respectively, RR 0.47, 95% CI 0.32 to 0.69, NNT 16, 95% CI 11 to 30). However, we found no significant difference between the study groups with respect to epigastric pain, taste disturbance/dry mouth, nausea, or abdominal gas/bloating (see figure 2) . Additionally, there was no significant difference between the groups in the frequency of vomiting, constipation, or other nonspecific reactions such as urticaria/skin reactions, palpitations, aphthous lesions in the mouth, belching, loss of appetite, blurred vision, or the presence of Clostridium difficile toxin.
The forest plots for these outcomes are not presented, as these outcomes have been reported in only one or two trials. The need for discontinuation of the eradication treatment was not reported in any trial.
DISCUSSION

Summary of evidence
This meta-analysis of RCTs showed that in patients with H pylori infection, addition of S boulardii to triple therapy compared with placebo or no intervention improved eradication rates, reduced overall therapy-related adverse effects, and decreased some individual symptoms such as diarrhoea. As the majority of included patients were adults, our results may be applicable primarily to such a population.
Quality of the evidence
In our analysis, the studies seemed methodologically sound with regard to sequence generation, >80% follow-up, and intention-to-treat analysis. Potential limitations included unclear or inadequate allocation concealment and no blinding in some 
How the intervention might work
The exact mechanisms by which S boulardii might exert its actions in increasing the eradication rates are unclear. One possible explanation is that this beneficial effect is due to a reduction in therapy-related side effects and, consequently, better compliance with treatment. Additional mechanisms, discussed in detail elsewhere, 24 include interference with pathogenic toxins, preservation of cellular physiology, interference with pathogen attachment, interaction with normal microbiota, or contribution to the reestablishment of short chain fatty acid levels. In addition, stimulation or modulation of immune responses, both within the lumen and systemically, although not clearly linked to H pylori infection, may also contribute.
Agreement and disagreement with other studies or reviews
With regard to the eradication rate, overall gastrointestinal side effects, and risk of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
effects of S boulardii supplementation on the rates of H pylori eradication, adverse effects, and patient compliance.
Our findings with regard to therapy-related diarrhoea are in line with and add to a previously published meta-analysis on the effects of S boulardii in preventing antibiotic-associated diarrhoea in children and adults. 25 This meta-analysis documented that treatment with S boulardii compared with placebo reduced the risk of antibiotic-associated diarrhoea from 17.2% to 6.7% (RR 0.43, 95% CI 0.23 to 0.78).
Of note, the effect size with respect to diarrhoea was similar in the current and previous meta-analyses (reduction of 53% vs 57%, respectively). Collectively, these data support the use of S boulardii for the prevention of diarrhoea associated with antibiotic treatment, regardless of the reason for which the antibiotics were used.
A number of studies suggest that the dose of probiotic is important. 26 27 28 29 The daily doses of S boulardii ranged from 500 mg to 1000 mg. The largest effect on the eradication rate was observed in the largest, but open-label, RCT by Song et al., 21 which used the daily dose of S boulardii 750 mg (corresponding to ≈22.5 x 10 9 CFU).
Whether or not this dose contributed to the beneficial effect of S boulardii on the eradication rate is not clear, but it could not be excluded.
Can we be satisfied with the eradication rate?
In 2007, Graham et al. 30 proposed that one judge the effectiveness of H pylori eradication therapy against an established target, such as a "report card." According to the proposed classification system, only therapies that score excellent, ie, those that achieve ≥95% eradication success in the local populations, should be prescribed. In our review, the H pylori eradication rate in the triple therapy group was 71% and increased to 80% with S boulardii supplementation. Thus, even when supplemented with S boulardii, this treatment did not achieve the desired level of success.
Nevertheless, when making clinical decisions, it seems reasonable to consider the mode of therapy with higher efficacy. Recently, it has been documented that 
CONCLUSIONS
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Eradication in adults
Cremonini (SB 500 mg) Song (SB 750 mg) Cindoruk (SB 1000 mg) Subtotal (95% CI) Total events Heterogeneity: Chi² = 0.35, df = 2 (P = 0.84); I² = 0% Test for overall effect: Z = 2.86 (P = 0.004)
Total (95% CI)
Total events Heterogeneity: Chi² = 0.47, df = 3 (P = 0.92); I² = 0% Test for overall effect: Z = 3.21 (P = 0.001) Test for subgroup differences: Not applicable Total events Heterogeneity: Tau² = 0.13; Chi² = 9.75, df = 4 (P = 0.04); I² = 59% Test for overall effect: Z = 3.60 (P = 0.0003)
Diarrhea
Cremonini (SB 500 mg) Song (SB 750 mg) Cindoruk (SB 1000 mg) Duman (SB 1000 mg) Subtotal (95% CI)
Total events Heterogeneity: Tau² = 0.00; Chi² = 1.31, df = 3 (P = 0.73); I² = 0% Test for overall effect: Z = 3.90 (P < 0.0001)
Epigastric pain
Cremonini (SB 500 mg) Song (SB 750 mg) Cindoruk (SB 1000 mg)
Subtotal (95% CI)
Total events Heterogeneity: Tau² = 0.30; Chi² = 4.75, df = 2 (P = 0.09); I² = 58% Test for overall effect: Z = 1.14 (P = 0.26)
Taste disturbance/dry mouth
Cremonini (SB 500 mg) Song (SB 750 mg) Cindoruk (SB 1000 mg) Duman (SB 1000 mg)
Subtotal (95% CI)
Total events Heterogeneity: Tau² = 0.17; Chi² = 4.47, df = 3 (P = 0.22); I² = 33% Test for overall effect: Z = 0.90 (P = 0.37)
Nausea
Subtotal (95% CI)
Total events Heterogeneity: Tau² = 0.00; Chi² = 0.45, df = 2 (P = 0.80); I² = 0% Test for overall effect: Z = 1.73 (P = 0.08)
Abdominal gas/bloating
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No
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
4
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
4-5
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
4
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
5
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
6
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 6
Synthesis of results
14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
2 ) for each meta-analysis.
6-7
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Risk of bias across studies
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).
7
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.
RESULTS
Study selection 17
Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.
7
Study characteristics
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
14-15 
DISCUSSION
Summary of evidence
24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
9
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
9-10
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
10-11
FUNDING
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